Global Car T Cell Therapy Market (2021 to 2028) - Size, Share, Outlook, and Opportunity Analysis
14 févr. 2022 05h43 HE
|
Research and Markets
Dublin, Feb. 14, 2022 (GLOBE NEWSWIRE) -- The "Car T Cell Therapy Market" report has been added to ResearchAndMarkets.com's offering. Chimeric antigen receptor (CAR) T-cell therapy is a type of...
The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030, claims Roots Analysis
06 avr. 2021 08h45 HE
|
Roots Analysis
London, April 06, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “CAR-T Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic...
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
23 nov. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four...
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
21 oct. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...
Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics
08 juin 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...
Chimeric Antigen Receptor (CAR) T-cell Therapy Market to See 44.1% Annual Growth
14 août 2018 07h00 HE
|
BCC Research
WELLESLEY, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Exciting developments in the world of immunotherapy are helping to drive incredible growth of the chimeric antigen receptor cell therapy market,...
Chimeric Antigen Receptor Market to See Explosive 44.1% Annual Growth Through 2023
08 août 2018 06h00 HE
|
BCC Research
WELLESLEY, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Exciting developments in the world of immunotherapy are helping to drive incredible growth of the chimeric antigen receptor cell therapy market,...
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy
22 mai 2017 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of...
Triumvira to Present Corporate Update at the Bloom Burton & Co. Healthcare Investor Conference
25 avr. 2016 08h30 HE
|
Triumvira Immunologics Inc.
HAMILTON, ON and HACKENSACK, NJ --(Marketwired - April 25, 2016) - Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a...